Table of Contents

Part I. Biology of Gynaecological Cancers: Our Current Understanding: 1. Morphological sub-types of ovarian carcinoma: new developments and pathogenesis W. Glenn McCluggage; 2. Novel treatment strategies for targeting genetic changes in endometrial cancer Susana Banerjee; 3. Epigenetic biomarkers in ovarian cancer Robert Brown and Janet Graham; 4. Predictive biology of ovarian cancer Christine A. Parkinson and James D. Brenton; Part II. The Translation of Biology to the Clinic: 5. Biology of BRCA1 and BRCA2 genes and implications for cancer management Timothy A. Yap, Yvette Drew and Susan Shanley; 6. Implications of homologous recombination defectiveness in ovarian cancer Richard J. Edmondson, Asima Mukhopadhyay, Aiste Cerbinskaite and Nicola J. Curtin; 7. The future of PARP inhibitors in the treatment of cancer Yvette Drew, Timothy A. Yap and Stan B. Kaye; Part III. Imaging and Therapy: State of the Art: 8. The role of robotics and the future Tim Mould; 9. 'Ultra-radical' surgery in advanced ovarian cancer Oliver Zivanovic and Dennis S. Chi; 10. Antivascular therapy in gynaecological cancers Leena Mukherjee and Gordon Rustin; 11. Oncolytic viral gene therapy in ovarian cancer Iain A. McNeish; 12. Endometrial cancer: what have the clinical trials taught us? Andrew Clamp; 13. Targeting therapies in cancer: opportunities in ovarian cancer Ahmed Ashour Ahmed, Stefan Knapp, Anil K. Sood and Robert C. Bast Jr; 14. Functional imaging: from tumour biology to the clinic Nandita M. deSouza, Evis Sala, Stavroula Kyriazi and Andrea Rockall; Part IV. What Questions Are Being Asked by Current Clinical Trials?: 15. Current clinical trials in ovarian cancer Christina Fotopoulou, Angus McIndoe, Jalid Sehouli and Hani Gabra; 16. Clinical trials in cervical cancer Karen Tipples and Melanie Powell; 17. Clinical trials in vulval cancer Tito Lopes; Part V. Consensus Views: 18. Consensus views arising from the 60th Study Group: Gynaecological Cancers: Biology and Therapeutics; Index.

Promotional Information

This book provides comprehensive coverage of gynaecological malignancies based on the 60th RCOG Study Group.

About the Author

Sean Kehoe works as a Consultant at Churchill Hospital and John Radcliffe Hospital, Oxford. He currently serves on the RCOG Council (as Fellows' Representative South East). Richard J. Edmondson is a Consultant at Queen Elizabeth Hospital, Gateshead. Martin Gore is Medical Director of The Royal Marsden and Professor of Cancer Medicine at The Institute of Cancer Research. Iain A. McNeish is a cancer specialist at Barts and the London School of Medicine, part of the Barts Cancer Research UK Centre. He is Deputy Director of the Barts Experimental Cancer Medicine Centre.